Scientists say vaccine temporarily brakes HIV

January 3, 2013

A team of Spanish researchers say they have developed a therapeutic vaccine that can temporarily brake growth of the HIV virus in infected patients.

The vaccine, based on exposed to that had been inactivated with heat, was tested on a group of 36 people carrying the virus and the results were the best yet recorded for such a treatment, the team said.

"What we did was give instructions to the so it could learn to destroy the virus, which it does not do naturally," said Felipe Garcia, one of the scientists in the team at Barcelona University's Hospital Clinic.

The , a shot that treats an existing disease rather than preventing it, was safe and led to a dramatic drop in the amount of detected in some , said the study, published Wednesday in Science Translational Medicine.

After 12 weeks of the trial, the HIV viral load dropped by more than 90 percent among 12 of the 22 patients who received the vaccine. Only one among the 11 patients who received a control injection without the vaccine experienced a similar result.

After 24 weeks, the effectiveness had begun to decline, however, with seven of the 20 remaining patients receiving the vaccine enjoying a similar 90-percent slump in viral load. No-one in the of 10 patients experienced such a decline in the virus.

The vaccine lost its effectiveness after a year, when the patients had to return to their regular of anti-retroviral drugs.

Researchers said the results were similar to those achieved with a single anti-retroviral drug, used to block the growth of HIV.

"It is the most solid demonstration in the scientific literature that a therapeutic vaccine is possible," they said in a statement.

The vaccine allowed patients temporarily to live without taking multiple medicines on a daily basis, which created hardship for patients, could have toxic side-effects over the long term and had a high financial price, the team said.

"This investigation opens the path to additional studies with the final goal of achieving a functional cure—the control of HIV replication for long periods or an entire life without anti-retroviral treatment," the researchers said in a statement.

"Although we still have not got a functional cure, the results published today open the possibility of achieving an optimal therapeutic vaccine, or a combination of strategies that includes a therapeutic vaccine, and could help to reach that goal," they said.

The team said it took seven years to get to this point, and the researchers would now work on improving the vaccine and combining it with other therapeutic vaccines over the next three or four years.

According to latest UN figures, the number of people infected by HIV worldwide rose to 34 million in 2011 from 33.5 million in 2010.

Explore further: Antibodies help protect monkeys from HIV-like virus, scientists show

More information: "A Dendritic Cell–Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication," by F. García et al, Science Translational Medicine.

Related Stories

Antibodies help protect monkeys from HIV-like virus, scientists show

May 5, 2011
Using a monkey model of AIDS, scientists have identified a vaccine-generated immune-system response that correlates with protection against infection by the monkey version of HIV, called simian immunodeficiency virus (SIV). ...

Non-human primate studies reveal promising vaccine approach for HIV

May 11, 2011
(PhysOrg.com) -- Research conducted at Oregon Health & Science University's Vaccine and Gene Therapy Institute (VGTI) has developed a vaccine candidate in non-human primates that may eventually lead to a vaccine against Human ...

Scientists probe how some HIV patients resist AIDS

October 1, 2012
(HealthDay)—Researchers who discovered an immune system mechanism that seems to provide some people with a natural defense against HIV say their finding could help efforts to develop a vaccine for HIV/AIDS.

Recommended for you

Paris spotlight on latest in AIDS science

July 21, 2017
Some 6,000 HIV experts gather in Paris from Sunday to report advances in AIDS science as fading hopes of finding a cure push research into new fields.

Scientists elicit broadly neutralizing antibodies to HIV in calves

July 20, 2017
Scientists supported by the National Institutes of Health have achieved a significant step forward, eliciting broadly neutralizing antibodies (bNAbs) to HIV by immunizing calves. The findings offer insights for HIV vaccine ...

Heart toxin reveals new insights into HIV-1 integration in T cell genome

July 20, 2017
Human immunodeficiency virus (HIV)-1 may have evolved to integrate its genetic material into certain immune-cell-activating genes in humans, according to new research published in PLOS Pathogens.

Scientists capture first high-resolution image of key HIV protein transitional state

July 13, 2017
A new, three-dimensional snapshot of HIV demonstrates the radical structural transformations that enable the virus to recognize and infect host cells, according to a new study led by scientists at The Scripps Research Institute ...

Barrier to autoimmune disease may open door to HIV, study suggests

July 11, 2017
Researchers from the University of Colorado School of Medicine have discovered that a process that protects the body from autoimmune disease also prevents the immune system from generating antibodies that can neutralize the ...

Team tests best delivery mode for potential HIV vaccine

June 20, 2017
For decades, HIV has successfully evaded all efforts to create an effective vaccine but researchers at The Scripps Research Institute (TSRI) and the La Jolla Institute for Allergy and Immunology (LJI) are steadily inching ...

3 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

El_Nose
not rated yet Jan 03, 2013
slowly but surely
JijiDuru
not rated yet Jan 03, 2013
slowly but surely


Yet, the "slowly" part accounts for millions of lives every year.
that_guy
not rated yet Jan 03, 2013
I want to know two things:
1 - Does this vaccine have any utility when used preventatively?
2 - What affect might this have when combined with anti-retrovirals rather than in lieu of then?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.